Does RISANKIZUMAB-RZAA Cause Breast cancer female? 307 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 307 reports of Breast cancer female have been filed in association with RISANKIZUMAB-RZAA. This represents 0.5% of all adverse event reports for RISANKIZUMAB-RZAA.
307
Reports of Breast cancer female with RISANKIZUMAB-RZAA
0.5%
of all RISANKIZUMAB-RZAA reports
2
Deaths
23
Hospitalizations
How Dangerous Is Breast cancer female From RISANKIZUMAB-RZAA?
Of the 307 reports, 2 (0.7%) resulted in death, 23 (7.5%) required hospitalization, and 1 (0.3%) were considered life-threatening.
Is Breast cancer female Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 307 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Breast cancer female?
RANITIDINE (7,563)
ADALIMUMAB (641)
ETANERCEPT (294)
INTERFERON BETA-1A (251)
LEVONORGESTREL (234)
DIMETHYL (221)
NATALIZUMAB (220)
UPADACITINIB (192)
DUPILUMAB (187)
VEDOLIZUMAB (168)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Breast cancer female Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA